Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

921 - Prediction model of low risk recurrence distinguished by 21-gene Recurrence Score in hormone receptor-positive invasive breast cancer: a validation study. (67P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Yasue Tsuchida

Citation

Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655

Authors

Y. Tsuchida1, N. Hayashi1, F. Omata2, S. Ohde3, Y. Kanada4, S. Tazawa5, M. Takimoto5, K. Suzuki6, S. Nakamura4, H. Yamauchi1

Author affiliations

  • 1 Breast Surgical Oncology, St Luke’s International Hospital, 1048560 - Tokyo/JP
  • 2 Center For Clinical Epidemiology, St Luke’s International Hospital, 1048560 - Tokyo/JP
  • 3 Graduate School Of Public Health, St Luke’s International Hospital, 1048560 - Tokyo/JP
  • 4 Breast Surgical Oncology, Showa University, school of medicine, 1428666 - Tokyo/JP
  • 5 Pathology, Showa University, school of medicine, 1428666 - Tokyo/JP
  • 6 Pathology, St Luke’s International Hospital, 1048560 - Tokyo/JP
More

Resources

Abstract 921

Background

The 21-gene Recurrence Score (RS) (Oncotype DX®; Genomic Health, Redwood City, CA) is the most valid and reliable multigene assay to predict prognosis or response to chemotherapy in hormone receptor-positive invasive breast cancer patients. In Japan, however, the test is not frequently used because of its expensive and no coverage by national insurance. We have developed a model to predict low recurrence risk (low-RS) using 220 patient data from St. Luke’s International Hospital, Tokyo, Japan (presented at San Antonio Breast Cancer Symposium 2016). The model with 4 factors, including the histologic type (invasive ductal or lobular), the expression level of PgR (Allred score 7,8 or  24), and the presence of lymphovascular invasion, showed that 92% of patients with high PgR positive and Ki67 < 24 could be classified as low-RS with an AUC of 0.843 (95%CI: 0.790-0.896). The aim of this study was to validate our prediction model with external patient data.

Methods

A validation set of clinicopathological data from 77 patients who had primary invasive carcinoma surgically resected and underwent OncotypeDx® was obtained from Showa University, school of medicine, Tokyo, Japan.

Results

According to the distribution of 4 factors between two cohorts, there was a significant difference in Ki67 level (

Conclusions

Regardless of the inconsistency of Ki67 level between institutes, our model could provide useful information to predict low-RS in hormone receptor-positive invasive breast cancer patients. This model would be helpful to select patients who had better apply OncotypeDX®.

Clinical trial identification

Legal entity responsible for the study

Yasue Tsuchida

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.